Description
Cagrilintide is a long-acting fatty acid-acylated amylin analog developed by Novo Nordisk, currently in Phase 3 clinical trials.
Published research includes:
→ Appetite regulation and satiety signaling via amylin receptor pathways
→ Gastric emptying rate reduction
→ Body weight reduction in Phase 2 clinical trials
→ CagriSema combination (Phase 3 data 2024) — additive weight loss beyond either compound alone
→ Glucose homeostasis research
Specifications:
• Developer: Novo Nordisk (Phase 3 clinical trials)
• Class: Amylin / Calcitonin receptor agonist
• Form: Lyophilized powder
• Purity: ≥98% (HPLC verified)
• Storage: Refrigerate 2–8°C | Freeze -20°C long-term
• Reconstitution: Bacteriostatic water
• Dose: 10 mg
⚠️ FOR RESEARCH PURPOSES ONLY. Not for human or animal consumption. Not a dietary supplement. Not FDA-approved. Certificate of Analysis available upon request — email info@hack3d.us
Reviews
There are no reviews yet.